The development of therapies targeting immune checkpoints, for example programmed death-ligand 1 (PD-L1), programmed cell death protein 1 (PD-1) as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) with immune checkpoint inhibitors (ICIs) has extraordinarily changed the course of melanoma treatment, currently making possible to fight advanced melanoma with remarkably higher success. This evidence concerns the gene CD274 and melanoma.